Spots Global Cancer Trial Database for Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer

Official Title: A Phase II, Randomized, Double-Blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients With Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Cancer Following Standard First-Line Endocrine Therapy

Study ID: NCT00166543

Conditions

Breast Cancer

Interventions

TAS-108

Study Description

Brief Summary: This study is being done to find out how safe TAS-108 is and how well TAS-108 works on recurrent or recurrent inoperable breast cancer.

Detailed Description: The objective of this study is to investigate the efficacy and safety of TAS-108 administered in postmenopausal patients with locally advanced or locally recurrent inoperable or progressive metastatic breast carcinoma who have previously responded to one or two standard endocrine therapies, with or without one prior chemotherapy.